Cargando…

Risk factors associated with an increase in the size of ground‐glass lung nodules on chest computed tomography

BACKGROUND: The detection rate of ground‐glass nodules (GGNs) in the lung has increased with the increased use of low‐dose computed tomography (CT) of the chest for cancer screening; however, limited data is available on the natural history, follow‐up, and treatment of GGNs. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hee‐Young, Bae, Ji‐Yun, Kim, Yookyung, Shim, Sung Shin, Park, Sojung, Park, So‐Young, Kim, Soo Jung, Ryu, Yon Ju, Chang, Jung Hyun, Lee, Jin Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610277/
https://www.ncbi.nlm.nih.gov/pubmed/31155851
http://dx.doi.org/10.1111/1759-7714.13098
Descripción
Sumario:BACKGROUND: The detection rate of ground‐glass nodules (GGNs) in the lung has increased with the increased use of low‐dose computed tomography (CT) of the chest for cancer screening; however, limited data is available on the natural history, follow‐up, and treatment of GGNs. The aim of this study was to identify factors associated with an increase in the size of GGNs. METHODS: A total of 338 patients (mean ages, 59.8 years; males, 35.5%) with 689 nodules who underwent chest CT at our institute between June 2004 and February 2014 were included in this study. The cut‐off date of follow‐up was August 2018. We analyzed the size, solidity, number, and margins of the nodules compared with their appearance on previous chest CT images. The Cox proportional hazard model was used to identify risk factors associated with nodule growth. RESULTS: The median follow‐up period was 21.8 months. Of the 338 patients, 38.5% had a history of malignancy, including lung cancer (8.9%). Among the 689 nodules, the median size of the lesions was 6.0 mm (IQR, 5–8 mm), and the proportion of nodules with size ≥10 mm and multiplicity was 17.1% and 66.3%, respectively. Compared to the nodules without an increase in size, the 79 nodules with an increase in size during the follow‐up period were initially larger (growth group, 7.0 mm vs. non‐growth group, 6.0 mm; P = 0.027), more likely to have a size ≥10 mm (26.6% vs. 15.9%; P = 0.018), and had less frequent multiplicity (54.4% vs. 67.9%, P = 0.028). In the multivariate analysis, nodule size ≥10 mm (hazard ratio [HR], 2.044; P = 0.005), a patient history of lung cancer (HR: 2.190, P = 0.006), and solitary nodule (HR: 2.499, P < 0.001) were independent risk factors for nodule growth. CONCLUSION: Careful follow‐up of GGNs is warranted in patients with a history of malignancy, a large , or a solitary nodule.